Schneider W. Contribution to the history of the sclerosing treatment of varices and to its anatomo-pathologic study. Bull Soc Fr Phlebol. 1965;18:117-30.

Goldman MP. Historical aspects of treatment. Treatment of varicose and teleangiectatic leg veins. 1995:1-10.

Porter JM, Moneta GL. Reporting standards in venous disease: an update. J Vasc Surg. 1995;21:635-45.

Goldman MP, Bennett RG. Treatment of telangiectasia: a review. J Am Acad Dermatol. 1987;17:167-82.

Weiss RA, Weiss MA, Goldman MP. Physicians' negative perception of sclerotherapy for venous disorders: review of a 7-year experience with modern sclerotherapy. South Med J. 1992;85:1101-6.

Smith FL, Johnson MA. Incidence of pulmonary embolism after venous sclerosing therapy. Minn Med J. 1948;31:270.

Guex JJ. Thrombotic complications of varicose veins: a literature review of the role of superficial venous thrombosis. Dermatol Surg. 1996;22:378-82.

Yamaki T, Nozaki M, Sasaki K. Acute massive pulmonary embolism following high ligation combined with compression sclerotherapy for varicose veins. Dermatol Surg. 1999;25:321-5.

Fegan WG. Continuous compression technique of injecting varicose veins. Lancet. 1963;2:109-12.

Beresford SA, Chant AD, Jones HO, Piachaud D. Varicose veins: a comparison of surgery and injection/compression sclerotherapy. Lancet. 1978;1:921-4.

Kakkar VV. Deep vein thrombosis of the leg. Am J Surg. 1970;120:527.

Williams RA, Wilson SE. Sclerosant treatment of varicose veins and deep vein thrombosis. Arch Surg. 1984;119:1283-5.

Bohler-Sommeregger K, Karnel F, Schuller-Petrovic S, Santler R. Do teleangiectases communicate with the deep venous system?. J Dermatol Surg Oncol. 1992;18:403-6.

Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-73.

Bertina RM, Koeleman B, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64-7.

Arruda VR, Annichino-Bizzacchi JM, Costa FF, Reistma PH. Factor V Leiden (FVQ 506) is common in a Brazilian population. Am J Hematol. 1995;49:242-3.

Franco RF, Reitsma PH, Lourenço D. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Throm Haemost. 1999;81:676-9.

Ridker PM, Glynn RJ, Miletich JP, Goldhaber SZ, Stampfer MJ, Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997;126:528-31.

Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. BMJ. 1996;313:1127-30.

Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost. 1996;75:524-5.